These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1407594)

  • 21. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impairment of renal function after intravenous immunoglobulin.
    Soares SM; Sethi S
    Nephrol Dial Transplant; 2006 Mar; 21(3):816-7. PubMed ID: 16399766
    [No Abstract]   [Full Text] [Related]  

  • 23. Surrogate therapeutic outcome measures in patients with myasthenia gravis.
    Zinman L; Baryshnik D; Bril V
    Muscle Nerve; 2008 Feb; 37(2):172-6. PubMed ID: 17918748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose intravenous gammaglobulin for myasthenia gravis.
    Fateh-Moghadam A; Wick M; Besinger U; Geursen RG
    Lancet; 1984 Apr; 1(8381):848-9. PubMed ID: 6200741
    [No Abstract]   [Full Text] [Related]  

  • 26. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis.
    Meiner Z; Ben-Hur T; River Y; Reches A
    J Neurol Neurosurg Psychiatry; 1993 Jul; 56(7):830-1. PubMed ID: 8380010
    [No Abstract]   [Full Text] [Related]  

  • 27. [Contribution of intravenous immunoglobulins to the treatment of myasthenia].
    Gajdos P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S30-4. PubMed ID: 10896986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis.
    Steg RE; Lefkowitz DM
    Neurology; 1994 Jun; 44(6):1180-1. PubMed ID: 8208421
    [No Abstract]   [Full Text] [Related]  

  • 29. [Aseptic meningitis as a complication of immunoglobulin treatment in myasthenia gravis].
    Puy-Nunez A; Dacosta-Balboa M; Cabo-Lopez I; Canneti B; Lopez-Ferreiro A; Rodriguez-Alvarez JR; Rodriguez-Regal A; Mourino-Sestelo MA
    Rev Neurol; 2016 May; 62(10):478-9. PubMed ID: 27149191
    [No Abstract]   [Full Text] [Related]  

  • 30. Simultaneous multiple cranial nerve neuropathies and intravenous immunoglobulin treatment in diabetes mellitus.
    Uluduz D; Bozluolcay M; Ince B; Kiziltan M
    Neurol India; 2006 Sep; 54(3):308-9. PubMed ID: 16936399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic steadily progressive central and peripheral predominantly motor demyelination, involving the cranial nerves, responsive to immunoglobulins.
    Bentes C; de Carvalho M; de Sá J; Luís ML
    Electromyogr Clin Neurophysiol; 1999; 39(1):33-7. PubMed ID: 10076759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IVIG in myasthenia gravis: getting enough "bang for the buck".
    Meriggioli MN
    Neurology; 2007 Mar; 68(11):803-4. PubMed ID: 17353466
    [No Abstract]   [Full Text] [Related]  

  • 34. Juvenile myasthenia gravis.
    Chiang LM; Darras BT; Kang PB
    Muscle Nerve; 2009 Apr; 39(4):423-31. PubMed ID: 19229875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG).
    Coghill J; Comeau T; Shea T; Braddy L; Bandarenko N; Afenyi-Annan A; Harvey D
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):786-8. PubMed ID: 16785068
    [No Abstract]   [Full Text] [Related]  

  • 36. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis.
    Silbert PL; Knezevic WV; Bridge DT
    Neurology; 1992 Jan; 42(1):257-8. PubMed ID: 1734312
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of myasthenia gravis].
    Rilling G; Tettenborn B
    Praxis (Bern 1994); 2001 Aug; 90(33):1350-4. PubMed ID: 11534319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.